Who is sponsoring NCT05265793?

NCT05265793 is sponsored by Fudan University.

What drugs are being tested in NCT05265793?

Interventions in NCT05265793: Camrelizumab Combined With Apatinib.

What condition does NCT05265793 study?

NCT05265793 studies PD-1 Immunotherapy, VEGFR-TKI, Sarcomatoid Carcinoma, Carcinosarcoma.

Is NCT05265793 still recruiting?

NCT05265793 is currently status unknown. Last updated 4 March 2022.

Last reviewed 2022-03-04 · How we verify

NCT05265793

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Status unknown Phase 2 Last updated 4 March 2022

What this trial tests

Phase 2 trial testing Camrelizumab Combined With Apatinib in PD-1 Immunotherapy in 45 participants. Status unknown.

Timeline

21 November 2021

Primary endpoint
30 March 2023

30 June 2023

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	21 November 2021
Primary completion	30 March 2023
Estimated completion	30 June 2023
Sites	1 location across China

Drugs / interventions tested

Camrelizumab Combined With Apatinib — full drug profile →

Conditions studied

PD-1 Immunotherapy — all drugs for PD-1 Immunotherapy →
VEGFR-TKI — all drugs for VEGFR-TKI →
Sarcomatoid Carcinoma — all drugs for Sarcomatoid Carcinoma →
Carcinosarcoma — all drugs for Carcinosarcoma →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with PD-1 Immunotherapy or VEGFR-TKI. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to explore the treatment of advanced sarcomatoid carcinoma or Carcinosarcoma with Carrelizumab combined with Apatinib, in order to provide guidance and experience for new combined therapy in clinic.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Frontiers of Ovarian Carcinosarcoma.
Ismail A, Choi S, Boussios S. · · 2023 · cited 18× · PMID 37938504 · DOI 10.1007/s11864-023-01138-4
Molecular Characterizations of Gynecologic Carcinosarcomas: A Focus on the Immune Microenvironment.
Nakad Borrego S, Lengyel E, Kurnit KC. · · 2022 · cited 6× · PMID 36139624 · DOI 10.3390/cancers14184465
Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review.
Wang L, Huang Y, Sun X. · · 2024 · cited 1× · PMID 38725630 · DOI 10.3389/fonc.2024.1362160
Metastatic Sarcomatoid Carcinoma of the Larynx: A Case Report.
Derfoufi J, Rezzoug F, Al Jarroudi O, Brahmi SA, et al · · 2024 · PMID 39463652 · DOI 10.7759/cureus.70331

Verify or expand the search:

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05265793 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 4 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05265793.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing